FEATURES >> Top 10 Women in Biotech
Top Story
Orexigen and Takeda ink a billion-dollar pact on weight loss drug
Orexigen has finally inked a deal on its weight-loss drug Contrave, accepting a relatively small $50 million upfront payment and more than a billion dollars in potential milestones from Japan's Takeda in exchange for North American marketing rights for a therapy that's about four months away from the FDA's finish line. Read more...
Latest News
Also Noted
@FierceBiotech: Helicos slaps PacBio with patent lawsuit. Article | Follow @FierceBiotech
@JohnCFierce: Interesting that it's the Japanese pharma companies jumping on board these obesity deals. | Follow @JohnCFierce
> Australia's Avexa says it has hired an advisor to take a hard look at its drug development assets and get back to the board with a plan for them. "We expect the review will provide the company with a clear picture of the potential value within Avexa's portfolio of assets," Avexa chairman Joe Baini said in a statement. Report
> The FDA has approved Actavis' app to market Atomoxetine HCl capsules for the treatment of attention deficit/hyperactivity disorder. Actavis release
Read more >>Press Releases
- Herbert A. Fritsche, Ph.D., former M.D. Anderson Cancer Center Professor and Scientist, joins Health Discovery Corporation as Se
- 'Charitable' Behavior Found in Bacteria
- Sinobiomed Announces New Chief Executive Officer
- Actavis Receives FDA Approval of Atomoxetine HCl Capsules
- Cetero Research Launches Seminar Series on Accelerated Proof-of-Concept in Drug Development
- Cardiome Achieves $30 Million Milestone
Latest Comments
More News
Top 10 Women in Biotech
It's a well-worn cliché that men dominate the top ranks of the biotech industry. But over the past decade a group of extraordinary women has put that cliché to the test. Perhaps one of the most interesting aspects of our selection of 10 women who have excelled in the industry is that there were so many outstanding women in biotechnology to choose from. Report
Special Report
Big Pharma's Top 5 Emerging Market Deals
With pharmaceutical sales in major markets like the United States, Europe and Japan slowing, a number of big drugmakers have looked outside of traditional territories to emerging markets. Eastern Europe, Russia, South America, the Middle East and Asia have all become sought-after markets as Big Pharma begins its emerging markets land-grab. Report